Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2017 Jan 1;28(1):7-8.
doi: 10.1093/annonc/mdw624.

'Genotype/immunotype' correlations in resected NSCLC

P K Paik  1   2 , M D Hellmann  1   2
Affiliations
Comment

'Genotype/immunotype' correlations in resected NSCLC

P K Paik et al. Ann Oncol. .
No abstract available

PubMed Disclaimer

Comment on

References

    1. Brahmer JR, Drake CG, Wollner I. et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28: 3167–3175. - PMC - PubMed
    1. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A. et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med 2016; 375: 1823–1833. - PubMed
    1. Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA. et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 2016; 17(11): 1497–1508. - PMC - PubMed
    1. Rizvi NA, Hellmann MD, Snyder A. et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer. Science 2015; 348: 124–128. - PMC - PubMed
    1. McGranahan N, Favero F, de Bruin EC. et al. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Sci Transl Med. 2015; 7: 283ra54. - PMC - PubMed